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Abstract 
 
Aim  
Regional utilisation of radical radiotherapy (RT) in non-small cell lung cancer 
(NSCLC) was used to define optimal utilisation to improve outcome and as a 
surrogate for evidence of RT efficacy.  
 
Patients & Methods 
65,412 NSCLC cases diagnosed in England 2012-13 were linked to comprehensive 
national radiotherapy dataset, hospital admissions and the Office of National 
Statistics. Geographical variation in utilisation was determined using a multivariate 
binary logistic regression analysis after adjusting for age, stage, deprivation, 
comorbidity and other radical treatment and the effect of radical RT utilisation on 
survival was investigated. Survival was adjusted for dependent and independent 
variables and the effect of differing levels of utilisation was assessed by the log 
likelihood test.  
 
Results 
17.6% cases potentially eligible for radical RT (stages 0-III) received radiotherapy 
with radical intent. Utilisation of radical RT had an impact on survival (p<0.00001).  
Adjusting for age, stage, deprivation index and comorbidity, counties with lowest 
utilisation (≤15%) had the worst survival (HR=1.13).  The highest utilisation quintile 
counties (≥25%) had worse survival compared to counties with lower utilisation 
(≈20%)(p<0.0001). Analysis of stages II&III showed the same pattern; increase in 
utilisation from 20% to ≥25% resulting in a 3% drop in 2-year population survival 
(p=0.001). 
 
Conclusion 
The utilisation of radical RT has a significant impact on NSCLC population survival. 
Improvement in survival of NSCLC population can be achieved by offering radical RT 
to a larger proportion of patients while avoiding excessive use. Geographical 
variation in RT utilisation provides indirect evidence of survival benefit of radical 
radiotherapy. 
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Introduction 
 
Radical external beam radiotherapy (RT) is the mainstay of treatment in patients with 
locally advanced and localised non-small cell lung cancer (NSCLC) not suitable for 
surgery.  While accepted as standard treatment, the magnitude of survival benefit of 
radical RT is not known as it has not been compared in randomised trials to a policy 
of no RT (1).  It is therefore difficult to promote the use of radical RT as a means of 
improving survival in NSCLC patient population. 
 
Nevertheless, radical RT has for many decades been accepted as an effective 
treatment and trials testing to what extent it would prolong survival would be difficult 
if not impossible to mount and it is unlikely such a randomised study of radical RT 
would be appropriate. Accepting that radiotherapy is effective in prolonging survival, 
regional variation in utilisation of radical RT may be associated with different 
outcomes. It has been noted that regional variation in the use of lung cancer surgery 
correlates with regional differences in lung cancer survival (2, 3), If an increase in RT 
utilisation was linked to improved survival this could be considered as a quasi-
experiment demonstrating the efficacy of radiotherapy.  
 
If increased radical RT utilisation was indeed associated with improved outcome it 
would be appropriate to understand its regional and national determinants to develop 
strategies to encourage optimal RT utilisation to improve survival in the lung cancer 
population. This is of particular relevance as lung cancer remains a malignancy with 
the highest mortality. 
 
Public Health England (PHE) and previously the National Clinical Analysis and 
Specialised Applications Team (NATCANSAT) collected comprehensive 
radiotherapy data (radiotherapy dataset – RTDS) from 2009 which gives a unique 
picture of radiotherapy utilisation throughout the country. Linking RTDS with other 
national data sources provides an opportunity to study the use of radiotherapy for 
specific disease indications and their impact on population survival.  
 
We report the analysis of the NSCLC national cohort linked to RTDS, Hospital 
Episode Statistics (HES) and survival data obtained from the Office of National 
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Statistics (ONS). Identifying potential regional variation in the use of radical 
radiotherapy resulting in differing outcomes provides the opportunity to improve the 
survival results in patients with NSCLC. In addition the geographical variation in 
radical RT utilisation can be considered as a surrogate to a trial of radical RT and its 
effect on survival.   
 
 
Methods 
 
Lung cancer cohort & survival 
A list of all non-small cell lung cancers (NSCLC) registered in England in 2012 and 
2013 was obtained from Public Health England. The selection criteria used were 
ICD10 codes: C33 - malignant neoplasm of the trachea or C34 - malignant 
neoplasm of bronchus and lung and morphology code M8046/3– non-small cell lung 
cancer; 65687 cases were identified. 
 
Data items obtained from the registry data base included NHS number, date of birth, 
diagnosis codes (ICD-10 topography and morphology codes), tumour laterality, 
stage of disease and postcode of residence – used to compute strategic cancer 
network (SCN), commissioning region, geographical area of residence (LSOA 
codes) and deprivation index (4).  
 
The NHS number was used to link the cancer records with survival data from Office 
of National Statistics (ONS). Two hundred and sixty seven cases could not be linked 
as no NHS number was recorded; these were excluded from the analysis. The 
remaining cases (65420) were followed via ONS records until 31st December 2015. 
Dates of death were obtained but not cause of death. As statutory death registration 
is required within 5 days (coroners cases may take longer) the survival data is as 
near to complete as possible. In the absence of a death registration, the assumption 
is that the lung cancer patient was alive on 31/12/2015. While deaths occurring 
abroad would not be known to the NHS and therefore missed, this is likely to 
represent a very small number of cases. After detailed review a further 8 cases were 
excluded as the recorded date of death was inconsistent with the date of diagnosis. 
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A total of 65412 cases diagnosed in England in 2012 and 2013 were subject to 
analysis. 
 
 
Geographical location 
The LSOA (Lower Layer Super Output Area) codes derived from the postcode of 
residence were used to allocate cases firstly to one of 348 administrative areas and 
then to ceremonial counties. To achieve geographical areas of broadly similar 
population size, London was split into ‘Inner London’ and ‘Outer London’ [rather than 
City of London & Greater London]. Due to small numbers, Rutland was combined 
with Leicestershire. This gave a total of 48 geographical areas (‘counties’). 
 
Radiotherapy 
The NHS number was used for linkage with the National Radiotherapy Dataset 
(RTDS), a centralised radiotherapy database to which all facilities providing 
radiotherapy services in England were required to return all details of prescriptions 
and treatment. Radiotherapy delivered in a private facility and funded privately is not 
recorded. All records of radiotherapy prescriptions to the primary (P), the primary & 
regional nodes (PR), regional nodes (R) or to non-anatomically specified primary site 
(A) were downloaded from the database and were used to create the treatment 
summary record (TSR). Data items of the TSR are total dose received (Gy), number 
of fractions, radiotherapy diagnosis (ICD-10 code) and treatment intent 
(radical/palliative). 
 
Surgery 
The NHS number was used for linkage with the Hospital Episodes Statistics (HES) 
database. Any lung excision procedures (lobectomy or pneumonectomy) that 
occurred within the time window of 6 months before to 18 months post diagnosis 
were recorded.  
 
Comorbidity 
Charlson comorbidity score (5) was calculated from diagnosis codes recorded in the 
HES database (6, 7) identifying the relevant diagnoses associated with admitted 
patient care episodes in the period from 30 to 3 months prior to diagnosis.  The HES 
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data does not include diagnoses of HIV and these were not included in the score. 
Lung cancer or metastatic cancer codes in this period were also excluded from the 
co-morbidity score.  
 
 
Data validation 
For the purpose of radical RT utilisation analysis only cases where radical 
radiotherapy might have been an appropriate treatment option were included. 
Radical RT is not generally an option for stage IV patients and 29478 cases with 
stage IV disease were excluded. 10242 cases where the stage was unknown were 
also excluded as “unknown” stage patients had a similarly poor survival as stage IV 
cases and the pattern of ‘radical’ RT was similar to the stage IV cases (1.5% of stage 
IV & 2.9% of unknown stage patients received >45Gy compared to 19% of stage 0-
III]. 25692 cases of stage 0 – III NSCLC were evaluated for the analysis of utilisation 
(Figure 1). 
 
Cases were selected for the cohort on the basis of a NSCLC diagnosis as recorded 
by the cancer registries. Because of inconsistencies in matching the cancer registry 
diagnosis and the radiotherapy diagnosis, all radiotherapy records for each patient 
were downloaded from the radiotherapy database. This included treatment to the 
primary lung tumour, to metastases and to second primaries. Radiotherapy records 
where the radiotherapy diagnosis was anything other than ‘neoplasms of respiratory 
and intrathoracic organs’ were subsequently excluded. After excluding non-lung 
radiotherapy records, 10376 patients (40.4%) received radiotherapy to the lung. 
Radiotherapy was classified as palliative, radical or SABR according to criteria in 
Table 1 checked against the initial coding. A further thirty three cases which could 
not be classified were excluded from the analysis. 
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Table 1  
Classification of radiotherapy into radical, palliative and unknown 
 
Dose fractionation Category Number 
of patients 
 
Total Dose > 100Gy Unknown 2 
< 1.5 Gy/# Unknown 17 
≥ 3Gy/#  and dose < 40Gy Palliative 4954 
Dose omitted and 1#, 10#, 12#, 13# Palliative 20 
Dose omitted and 5 # and stage ≠ 1 Palliative 22 
> 3Gy/# and dose ≥ 40Gy  and > 
10# 
Radical  77 
1.5 – 3Gy/# Radical  4342 
Dose omitted and ≥ 20Gy/# Radical  108 
≥ 3 Gy / # and dose ≥ 40Gy and ≤ 
10# 
SABR 770 
Dose omitted and 5 # and stage = 
1 
Unknown  
(possibly SABR) 
analysed as SABR 
31 
Remainder Unknown 33 
 
# - fraction of radiotherapy; radical – fractionated radical radiotherapy; SABR – 
stereotactic ablative body radiotherapy 
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Figure 1 
Flowchart of cases of NSCLC identified and included in the utilisation analysis 
 
 
Statistical Methods 
The effect of variables on the utilisation of radiotherapy was investigated in a 
univariate analysis and the significance of differences assessed by the chi-squared 
test or chi-squared test for trend. A multivariate binary logistic regression analysis 
was done to determine the utilisation in each of the counties after adjusting for the 
effect of age, stage, deprivation, comorbidity and other radical treatment (defined as 
lung excision or SABR). Significance was assessed by the Wald chi-squared test. 
The adjusted utilisation rates were used to rank the counties in order of increasing 
radical utilisation rates. Tertiles and quintiles were used to classify the counties as 
having low, medium or high (very low, low, medium, high and very high) utilisation. 
 
 
65687 NSCLCs identified 
by cancer registries 
(N=267) 
Followed up at ONS 
(N=65420) 
NHS no 
recorded 
No 
Inconsistent death 
date (N=8) 
Linked to radiotherapy 
dataset (N=65412) 
Stage 0 – III   
(N=25692) 
Stage IV 
(N=29478) 
Unknown Stage 
(N=10242) 
Radiotherapy could not 
be classified (N=33) 
Stage 0 – III for 
analysis (N=25659) 
9 
 
Figure 2  
Utilisation of radical radiotherapy by geographical area separated into 3 and 5 
utilisation groups 
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Table 3 
Rates of radical radiotherapy utilisation by County;  
Raw data adjusted for age stage and deprivation decile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  % radical radiotherapy  
 
County 
code 
 
No 
cases 
 
Unadjusted 
Adjusted for age, stage, 
deprivation, comorbidity, 
other radical treatment 
 
Significance 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
233 
294 
260 
252 
385 
799 
457 
243 
288 
476 
550 
353 
481 
424 
413 
838 
327 
943 
676 
77 
397 
856 
64 
844 
1572 
368 
474 
1210 
485 
420 
302 
202 
528 
1500 
279 
241 
326 
813 
510 
348 
435 
934 
176 
1350 
340 
1464 
231 
221 
12.4% 
9.9% 
6.2% 
11.5% 
21.6% 
23.4% 
29.1% 
30.5% 
17.4% 
13.0% 
17.3% 
19.8% 
22.2% 
16.7% 
12.1% 
10.6% 
8.3% 
33.7% 
16.7% 
6.5% 
9.3% 
20.9% 
23.4% 
15.5% 
25.1% 
13.9% 
15.2% 
16.5% 
21.4% 
24.8% 
9.9% 
17.3% 
15.0% 
16.5% 
9.7% 
9.5% 
8.6% 
17.7% 
14.3% 
20.4% 
19.1% 
18.7% 
14.2% 
13.4% 
13.8% 
19.4% 
10.0% 
11.8% 
13.1% 
8.6% 
5.0% 
10.7% 
20.9% 
23.7% 
31.7% 
30.5% 
16.5% 
13.8% 
16.3% 
18.5% 
22.5% 
17.4% 
10.9% 
10.0% 
7.2% 
37.9% 
14.5% 
5.5% 
8.7% 
20.0% 
19.7% 
13.9% 
24.7% 
13.4% 
15.9% 
18.2% 
21.5% 
26.0% 
9.5% 
15.6% 
15.5% 
15.7% 
10.2% 
8.7% 
8.3% 
17.9% 
13.4% 
19.3% 
19.2% 
18.9% 
12.6% 
13.3% 
12.2% 
21.8% 
8.9% 
10.4% 
 
Unadjusted :  
 
P <<  0.00001 
χ 2 test  
 
 
Adjusted :  
 
P<< 0.00001 
Wald  
chi-squared 
test 
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The effect of differing levels of radical radiotherapy utilisation on survival was 
investigated in a multivariate Cox regression analysis. The assumption of 
proportional hazards was confirmed by log minus log plots. Survival was adjusted for 
age, stage, deprivation, comorbidity and other radical treatment and differences 
between the county tertiles (quintiles) were assessed by the log likelihood test. 
Results for each utilisation group were summarised by the hazard ratio relative to the 
tertile (quintile) with the greatest utilisation.  
 
The primary objective of the study was to look at differences in the utilisation of 
fractionated radical radiotherapy. Since a low utilisation could be compensated by a 
higher use of SABR, the analysis adjusted for this factor. As SABR is almost entirely 
restricted to stage I patients, a further sensitivity analysis was carried out for stage II 
and III patients alone. 
 
Results 
 
Utilisation of Radical Radiotherapy 
Overall 17.6% of patients with NSCLC potentially eligible for radical treatment intent 
received fractionated radical radiotherapy (Table 2). There was an increase in the 
rate of radical radiotherapy with the stage of disease from 11.8% for stage 0/I to 
21.4% for stage III. There was a gradual decrease in radical radiotherapy utilisation 
with age from the highest utilisation in the 40-59 age group (Table 2). Utilisation was 
highest (19.6%) in the most deprived areas and lowest (14.7%) in the least deprived. 
Patients with comorbidity scores of 2 or more had lower rates of radical radiotherapy 
utilisation.  
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Table 2 
Rates of radical radiotherapy utilisation in stages 0 – III NSCLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The use of fractionated radical radiotherapy varied across the counties (Table 3). As 
utilisation is likely to be affected by prognostic and treatment variables, the rates for 
the counties were calculated after adjusting for age, stage, deprivation, comorbidity 
and other radical treatment (Figure 2 & Table 3).  
 
 
 
Characteristic  No. cases Radical RT % radical RT significance 
 
All cases 
 25659 4527 17.6%  
Stage of 
disease 
0 
I 
II 
III 
117 
8717 
4878 
11947 
18 
1025 
929 
2555 
15.4% 
11.8% 
19.0% 
21.4% 
 
P<< 
0.00001 
χ
2
 test for 
trend 
Age < 40 
40 – 49 
50 – 59 
60 – 69 
70 – 79 
80 – 89 
>= 90 
50 
429 
2222 
7059 
9286 
5863 
750 
10 
119 
571 
1520 
1615 
665 
27 
20.0% 
27.7% 
25.7% 
21.5% 
17.4% 
11.3% 
3.6% 
 
P <<  
0.00001 
χ 
2
 test for 
trend 
Deprivation 
decile 
 
1 – most 
deprived 
2 
3 
4 
5 
6 
7 
8 
9 
10-least 
deprived 
3839 
3209 
2985 
2756 
2544 
2498 
2312 
2119 
1892 
1505 
751 
609 
531 
452 
439 
431 
388 
357 
348 
221 
19.6% 
19.0% 
17.8% 
16.4% 
17.3% 
17.3% 
16.8% 
16.8% 
18.4% 
14.7% 
 
P =  0.0001 
χ 
2
 test for 
trend 
Comorbidity 0 
1 
2 
3 
4 
5 
6 + 
16840 
3962 
2481 
1232 
619 
311 
214 
3186 
687 
321 
175 
88 
41 
29 
18.9% 
17.3% 
12.9% 
14.2% 
14.2% 
13.2% 
13.6% 
 
P <<  
0.00001 
χ 
2
 test  
Other radical 
treatment 
None 
Surgery 
/ SABR 
17045 
8614 
3824 
703 
22.4% 
8.2% 
P <<  
0.00001 
Fishers 
exact test  
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Radical RT Utilisation and Survival 
By Dec 31st 2015, 15956 of the NSCLC patients (62.2%) had died. Age, stage, 
comorbidity and other radical treatment were all independent significant predictors of 
survival whilst deprivation was of marginal significance. After adjusting for these 
factors, the utilisation of radical radiotherapy had an impact on survival (p<0.00001). 
Dividing the counties into 3 groups, those with the highest utilisation had the best 
overall survival (Table 4) (2 year survival 48.6%) compared to medium (2 year 
survival 45.4%) and low utilisation (2 year survival 44.3%). Dividing the counties into 
5 groups according to radiotherapy utilisation the counties with the highest utilisation 
had poorer survival (2 year survival 47.5%) than those in the second lower utilisation 
group (2 year survival 49.1%) (Table 4).  
 
Based on the optimal level of utilisation, the data indicate that the lives of an 
additional 346 (95% CI: 284 – 406) lung cancer patients per year could have been 
extended beyond 2 years. 
 
Of the 801 SABR cases, 712 (89%) were stage 0 / I. As a sensitivity test, the 
analysis was repeated for stage II and III patients alone. In this poorer survival 
group, differing levels of radical fractionated radiotherapy utilisation showed the 
same pattern of survival (Table 4). Dividing the cohort into three groups, those 
counties with the highest utilisation had a 2 year survival of 34.1% compared to 
31.6% in the medium and 30.0% in the lowest utilisation groups (Table 4). Dividing 
the counties into 5 groups according to radiotherapy utilisation the counties with the 
highest utilisation had a worse survival (2 year survival 32.9%) compared to counties 
with lower utilisation (2 year survival 36.1%)  
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Table 4 
Hazard ratios (HR) relative to the highest utilisation group divided into 3 
groups (tertiles) and 5 groups (quintiles) for stages 0 – III NSCLC cases 
(n=25659) (A) and for stages II & III (n=16825) (B). 
 
A 
 
tertiles HR* 95% CI* Significance  2 yr. survival* 
Low utilisation 1.13 1.08 – 1.18 p<0.001 44.3% 
Medium 1.09 1.06 – 1.13 p<0.001 45.4% 
High utilisation 1.0   48.6% 
     
quintiles     
Very Low utilisation 1.09 1.04 – 1.15 p=0.001 44.1% 
Low 1.10 1.05 – 1.16 p<0.001 44% 
Medium 1.05 1.00 – 1.09 P=0.05 46% 
High  0.95 0.91 – 1.00 P=0.04 49.1% 
Very high utilisation 1.0   47.5% 
 
B 
 
tertiles HR* 95% CI* Significance 2 yr. survival* 
Low utilisation 1.13 1.08 – 1.18 p<0.001 30.0% 
Medium 1.08 1.04 – 1.13 p<0.001 31.6% 
High utilisation 1.0   34.1% 
     
quintiles     
Very Low utilisation 1.08 1.02 – 1.15 p=0.012 30.1% 
Low 1.10 1.04 – 1.17 p=0.001 29.4% 
Medium 1.03 0.98 – 1.08 p=0.3 31.7% 
High  0.92 0.87 – 0.97 p=0.001 36.1% 
Very high utilisation 1.0   32.9% 
 
CI - confidence interval 
* corrected for age, stage, deprivation index & comorbidity 
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Discussion 
 
The analysis of the population of patients diagnosed with non-small cell lung cancer 
(NSCLC) in England in a 2 year period from January 2012 to December 2013 shows 
marked geographical variation in the use of radical radiotherapy (RT) and increased 
utilisation of RT is associated with improved NSCLC population survival. It also 
provides supporting evidence that radical RT in patients with locally advanced 
NSCLC is likely to be effective in prolonging survival.  
 
The relationship between RT utilisation and survival is not linear. Although not 
previously demonstrated for surgery (3) or RT (2) it would fit with the hypothesis that 
only a proportion of patients with locally advanced NSCLC are suitable for radical RT 
most likely due to a combination of comorbidity, poor performance status, tumour 
size, age and other potential prognostic factors. This suggests that offering radical 
treatment to patients with poor predicted outcome is unlikely to overcome some of 
the determinants of the adverse prognosis and may even be detrimental.  
 
The relationship between utilisation of radical treatment and outcome in patients with 
NSCLC has been demonstrated for surgery (3) and for other oncological treatments  
although the study looked at all lung cancer rather than NSCLC alone (2). The 
potential “optimum” utilisation has been suggested but not previously shown.  
 
The data and the analysis are subject to potential bias. Although the survival 
endpoint in a population in England is reliable, some of the variables analysed may 
be affected by inaccuracy inherent in a large population study where data recording 
is not subject to detailed scrutiny. For example this may be an issue when defining 
treatment intent particularly when the analysis of outcome should be by treatment 
intent rather than treatment delivered.  
 
The RT data is part of RT data set (RTDS) collected by NATCANSAT directly from 
radiotherapy providers using software which extracts data from Oncology 
Management Systems, and subject to a standard set of quality assurance measures 
upon receipt.  This ensures that the dataset is complete (i.e. includes all patients 
treated), accurate and of acceptable quality. 
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To avoid or at least minimise bias inherent in an analysis by “treatment delivered”, 
discrepancies between stated treatment intent and actual treatment delivered were 
individually analysed and allocated based on an algorithm shown in Table 1.  This 
ensures that patients receiving lower than planned doses who are assumed to have 
stopped treatment early are correctly allocated to radical rather than palliative 
treatment intent. Similarly, the results could be skewed by increasing use of 
stereotactic ablative body radiotherapy (SABR) given to patients with localised 
disease where the outcome is considered to be equivalent to surgery (8, 9). To avoid 
bias, SABR patients were grouped with patients treated with attempted curative 
surgery and not included in the RT utilisation analysis. It is therefore likely that the 
RT utilisation rate reported here is reasonably accurate and represents the actual 
delivery of fractionated radical RT to patients with localised and locally advanced 
NSCLC in England in the study period. 
 
Other factors may determine the outcome in addition to RT utilisation. Known 
measurable predictors of outcome which vary with RT utilisation including age, 
comorbidity, stage and the use of surgery were corrected for in the analysis. The 
missing factors are performance status and the use of systemic anticancer therapy 
(SACT). 
 
Performance status (PS) information was not nationally recorded. Comorbidity index, 
particularly derived from HES data, while potentially not fully representative of 
performance status is a reasonable surrogate used in other studies (10). However an 
effect of PS on the reported outcomes independent of age and comorbidity cannot 
be excluded. 
 
In the study period (2012-13) SACT data was not routinely collected on national 
basis and is not easily accessible particularly for such a large cohort. An expected 
survival benefit of adjuvant chemotherapy of the order of 5% (11) (12) in the 
population of patients treated, even if all patients in the high utilisation regions and 
none in the low utilisation regions received chemotherapy, is unlikely to translate to 
the reported increase in population survival. As only a proportion of patients treated 
with radical RT also receive chemotherapy a potential variation in utilisation is 
17 
 
unlikely to significantly influence the reported outcome and this was demonstrated in 
a lung cancer population study where the utilisation of chemotherapy was not 
associated with an overall survival difference (2). Similarly the use of concomitant 
compared to sequential chemoradiotherapy (13) even if correlated with utilisation, is 
unlikely to be responsible for the reported population difference.  
 
The reported results raise the issue of the potential determinants of utilisation that 
could be altered to improve survival particularly in patients with locally advanced 
NSCLC. Age and comorbidity are likely to be dependent rather than independent 
predictors. Deprivation index had only minimal association with utilisation which 
suggests that the variation in radical RT utilisation is not primarily determined by 
socio-economic status. 
 
The analysis of differential utilisation was carried out by ceremonial counties and not 
regions identified by healthcare provider. Such analysis should however be carried 
out best by healthcare authorities to identify if the differences are provider specific. 
From the available data there is no significant correlation between the number of 
cases of NSCLC in the county and RT utilisation (data not shown). While there is no 
clear geographical distribution of utilisation, assessment such as proximity to RT 
centres has not been examined and may be of importance as geographical access 
to cancer services has impact on survival (14). 
 
Conclusion  
The utilisation of radical RT is an important and independent determinant of survival 
in patients with localised and locally advanced NSCLC. On the basis of the available 
evidence, health authorities should ensure that RT providers offer radical treatment 
to a larger proportion of patients suitable for radical RT while avoiding excessive use 
in patients considered unsuitable for radical treatment.  
 
 
 
 
 
18 
 
References: 
 
1. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer 
in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic 
review. Thorax. 2001 Aug;56(8):628-38. PubMed PMID: 11462066. 
2. Moller H, Coupland VH, Tataru D, Peake MD, Mellemgaard A, Round T, et al. 
Geographical variations in the use of cancer treatments are associated with survival of lung 
cancer patients. Thorax. 2018 Jun;73(6):530-7. PubMed PMID: 29511056. 
3. Riaz SP, Luchtenborg M, Jack RH, Coupland VH, Linklater KM, Peake MD, et al. 
Variation in surgical resection for lung cancer in relation to survival: population-based study 
in England 2004-2006. Eur J Cancer. 2012 Jan;48(1):54-60. PubMed PMID: 21871792. 
4. Government DoCaL. English indices of deprivation 2015. 2015. 
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic 
diseases. 1987;40(5):373-83. PubMed PMID: 3558716. 
6. Gildea G MS, Greenberg D, Price G, Francis  M, Thomson CS, Poole J. Derivation of 
a Charlson co-morbidity index from routine HES data. 
7. Maringe C, Fowler H, Rachet B, Luque-Fernandez MA. Reproducibility, reliability and 
validity of population-based administrative health data for the assessment of cancer non-
related comorbidities. PloS one. 2017;12(3):e0172814. PubMed PMID: 28263996. Pubmed 
Central PMCID: 5338773. 
8. Solda F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic 
radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic 
review and comparison with a surgical cohort. Radiother Oncol. 2013 Oct;109(1):1-7. 
PubMed PMID: 24128806. 
9. Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S, et al. Matched-pair comparisons of 
stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-
small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014 
Aug;112(2):250-5. PubMed PMID: 25236716. 
10. Henson KE, Fry A, Lyratzopoulos G, Peake M, Roberts KJ, McPhail S. 
Sociodemographic variation in the use of chemotherapy and radiotherapy in patients with 
stage IV lung, oesophageal, stomach and pancreatic cancer: evidence from population-
based data in England during 2013-2014. Br J Cancer. 2018 May 10. PubMed PMID: 
29743552. 
11. Group N-sCLCC. Chemotherapy in non-small cell lung cancer: a meta-analysis using 
updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung 
Cancer Collaborative Group. Bmj. 1995;311(7010):899-909. PubMed PMID: 7580546. 
12. Auperin A, Le Pechoux C, Pignon JP, Koning C, Jeremic B, Clamon G, et al. 
Concomitant radio-chemotherapy based on platin compounds in patients with locally 
advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 
patients. Ann Oncol. 2006 Mar;17(3):473-83. PubMed PMID: 16500915. 
13. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-
analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-
cell lung cancer. J Clin Oncol. 2010 May 01;28(13):2181-90. PubMed PMID: 20351327. 
14. Murage P, Crawford SM, Bachmann M, Jones A. Geographical disparities in access 
to cancer management and treatment services in England. Health & place. 2016 Nov;42:11-
8. PubMed PMID: 27614062. 
19 
 
 
 
